Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229293 | 0.82 | NQO1 (0.36) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL1697679 | 0.81 | SMN1; SMN2 (0.42) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL160948 | 0.81 | NQO1 (0.48) | L3MBTL1NPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2221457 | 0.79 | PLAU (0.38) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL12523295 | 0.79 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL15740900 | 0.76 | NR5A1 (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL8123046 | 0.76 | NR5A1 (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL22895687 | 0.74 | CCNK (0.36) | NCF1L3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15578234 | 0.73 | SMN1; SMN2 (0.36) | L3MBTL1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL15219240 | 0.73 | NCF1 (0.49) | NCF1L3MBTL1THRAPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4305031-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022187964-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | adMare Therapeutics Society (CA) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | NCF1 1633/4885L3MBTL1 428/4885THRA 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.